INTRODUCTION
Pancreatic ductal adenocarcinoma (PDAC) is an extremely aggressive malignancy with poor prognosis. The overall 5-year-survival rate is only < 5%. A rapid disease progression and absence of specific symptoms often preclude early diagnosis and curative treatment.
Approximately 80% of the patients have an advanced disease with distant metastases at diagnosis, and only 10-20 % are accessible for surgical resection (1) . Occasional resistance of PDAC to chemotherapy demanded alternative therapeutic approaches (2, 3) . An increasing number of novel therapeutic strategies including targeted therapy or immunotherapy alone or in combination with chemotherapy have been described but still failed to considerably improve survival times of the patients (4, 5) .
Immunotherapy with unconventional T-cells such as γδ T-cells is of substantial interest based
on their potent HLA-non-restricted cytotoxicity against different tumor entities and their additional capacity to recognize and present antigens to αβ T-cells (6) (7) (8) . Several pilot studies reported a partial success in tumor reduction after in vivo activation of γδ T-cells with nitrogen-containing-bisphosphonates (n-BP) and rIL-2 or after adoptive transfer of in vitro activated γδ T-cells (9) (10) (11) (12) . Vγ9Vδ2 γδ T-cells recognize isopentenyl-pyrophosphate (IPP) of the eukaryotic mevalonate pathway, a phosphoantigen (PAg) whose production is enhanced in dysregulated transformed cells. The augmented production of IPP in tumor cells is further increased by treatment with n-BP such as zoledronic acid (13) . Comparable to IPP, synthetic phosphoantigens (PAg) such as bromohydrin pyrophosphate (BrHPP) are also capable of inducing activation of Vγ9Vδ2 T-cells (14) . We have previously shown the efficacy of human Vγ9Vδ2 T-cells from healthy donors against PDAC in vitro as well as in vivo after repetitive adoptive transfer of γδ T-cells together with n-BPs and low dose IL-2 into SCID mice (15) .
Although γδ T-cell-based immunotherapy delivered promising results, it is mandatory to
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Author Manuscript Published OnlineFirst on January 21, 2014; DOI: 10.1158/0008-5472. optimize the cytotoxic activity of tumor-reactive γδ T-cells in view of an observed exhaustion of γδ T-cells, and to minimize the repetitive adoptive γδ T-cell transfer (7, 8, 15, 16) .
To date, the most promising approach to enhance the cytotoxic potential and to recruit T-cells to the tumor is based on the usage of single-chain bispecific antibody constructs of the bispecific T-cell engager (BiTE) class (17) . BiTE antibodies such as blinatumomab with specificity for CD3 on T-cells and for CD19 on lymphoma or leukemia cells have proved to be efficient for the treatment of patients with hematological malignancies (18, 19) .
In this study, we designed two novel bispecific antibodies with specificity for CD3 or Vγ9TCR on γδ T-cells and for receptor tyrosine kinase Her2/neu, which is over-expressed on 11 to 82% of tumor cells of PDAC-patients (20) (21) (22) (23) . We investigated the potential of these novel bispecific antibodies to enhance the cytotoxicity of γδ T-cells from PDAC-patients measured in vitro with a Real Time Cell Analyzer (RTCA) and in vivo upon adoptive transfer into PDAC-bearing SCID-Beige mice. In addition, we established an immune monitoring system to determine the absolute cell number of γδ T-cell subsets of PDAC-patients ex vivo. To establish short-term γδ T-cell lines, PBMC were cultured in RPMI 1640 supplemented with 2 mM L-glutamine, 25 mM HEPES, antibiotics, 10% FCS (complete medium), and stimulated either with 300 nM of PAg BrHPP (kindly provided by Innate Pharma, Marseille, France) or 5 μM of n-BP zoledronic acid (Novartis, Basel, Swiss). 50 U/ml rIL-2 (Novartis)
Research. was added every two days over a culture period of 14 to 21 days. After 2-3 weeks, most γδ Tcells had a purity > 95% Vγ9Vδ2 γδ T-cells. CD8 αβ T-cell lines were established from PBMC of PDAC-patient 13 after stimulation with 0.5 μg/ml phytohemagglutinin (Thermo Fisher Scientific). CD8 αβ T-cells were purified by magnetic depletion of non-CD8 T-cells and expanded by feeder cells and phytohemagglutinin (15) . Further details are given in the supplemental Material and Methods. Construction of the recombinant bispecific antibody derivatives. The CD3-and CD19-single-chain fragment variables (scFv) were synthesized according to published sequences (24, 25) . Appropriate restriction sites were introduced to allow directional cloning into a pSEC-Tag2-Hygro-CD20xCD16 vector allowing secretion of bispecific scFv (bsscFv) (unpublished). The CD20-scFv was replaced by the CD19-or Her2-specific scFv described earlier (26) . The final expression vectors pSEC-Tag2-Hygro-Her2xCD3, pSEC-Tag2-HygroCD19xCD3 and pSEC-Tag2-Hygro-CD20xCD3 were partially sequenced to confirm success of the cloning procedure.
The coding sequences for the variable regions of the Vγ9 γδ T-cell-specific antibody (clone 7A5) were isolated according to established procedures (27, 28) . Cloning cassettes for the integration in expression vectors allowing generation of bispecific antibodies in the tribody format were de novo synthesized (Entelechon GmbH, Regensburg). Secretion leaders and appropriate restriction sites were introduced to allow directional cloning into expression 
Statistical analysis
The statistical analysis of immune monitoring was assessed by Wilcoxon rang sum test using SPSS version 17.0. All statistical tests were two-sided and the level of significance was set at 5%, not corrected for multiple testing.
Since no violation of normal distribution assumption was found (Shapiro-Wilk test), all statistical comparisons of the in vivo experiments were done parametrically by using t-tests. We focused in this study on numerically reduced Vδ2 T-cells, which are exclusive targets for PAg applied in γδ T-cell-based immunotherapy. We established several short-and longtermed-cultured Vδ2 T-cell lines from PDAC-patients as well as from healthy donors (Fig.   S1A ). In previous studies, we observed a limited cytotoxic capacity of Vδ2 T-cell lines from healthy donors against PDAC-cell lines which, however, could be enhanced by the addition of PAg or n-BP (15) . A sustained stimulation of Vδ2 T-cells by PAg or n-BPs often leads to an exhaustion of the γδ T-cell pool, which requires novel or modified stimulation protocols (7).
Combining γδ T-cell-based immunotherapy with mAb provides novel perspectives. An enhanced efficacy against Her2 + breast cancer cells has been described after adoptive transfer of expanded γδ T-cells together with a humanized anti-Her2/neu mAb (trastuzumab) into human Her2 + mammary carcinoma-bearing SCID mice (32) . A recent review summarized the evidence that the combination of γδ T-cell-based immunotherapy with mAb in general exerts
Research. a considerable therapeutic potential for a variety of malignancies (33) . In all these studies, γδ T-cells bind to mAb labeled tumor cells via FcRγIII (CD16) and thereby exert antibodydependent cell-mediated cytotoxicity. We observed a high donor-dependent variability of CD16 expression on γδ T-cells from PDAC-patients (data not shown). This observation together with the observed expression of Her2/neu on the surface of all analyzed PDAC-cell lines (Fig. S1B) prompted us to design a bispecific antibody in a BiTE-like tandem scFv format by genetically fusing a scFv derived from the trastuzumab V-regions to a CD3-specific scFv via a flexible linker (Fig. S2A/B) . The comparison of γδ T-cell lines established from healthy donors or PDAC-patients showed a very similar cytotoxic activity against the indicated PDAC-cell lines, as revealed in a 51 Crrelease assay (Fig. 2) . In the absence of any additional stimulus, the γδ T-cell-mediated cytotoxicity against all PDAC-cell lines was very weak ( Fig. 2A, S3A ). We then examined several strategies to enhance the poor cytotoxic capacity of γδ T-cells against the PDAC-cells by comparing the enhancing effects of PAg and bispecific ab. As expected, the addition of PAg enhanced the cytotoxic activity of γδ T-cells from healthy donors (Fig. 2B, S3B ). We obtained similar results using γδ T-cells of PDAC-patients instead of healthy donors (Fig.   2B ). The addition of a previously titrated optimal concentrations of [Her2xCD3] to the PAgstimulated cells further increased cytotoxic activity compared to the PAg stimulation in combination with the control bsscFv (Fig. 2C/D, S3C/D) . Moreover, the [Her2xCD3] alone was sufficient to moderately enhance cytotoxicity of γδ T-cells against PDAC-cells in comparison to PAg alone or the combination of both (Fig. 2E, S3E ). Interestingly, γδ T-cell lines established from a given donor exerted similar cytotoxic activity independently of whether the cells were used after initial-or after re-stimulation (Fig. 2, S3 , HD3/PC1 and data not shown).
Comparison of 51 Cr-release and RTCA-SP assay
Bispecific antibodies engaging CD3 display enhanced cytotoxicity when it is measured for prolonged time intervals (35) . The chromium release assay just gives a snap-shot of γδ T-cell cytotoxicity against tumor cells as it is usually measured after 4 h of incubation. Therefore, we used in parallel the RTCA-SP assay which monitors cellular events without the incorporation of labels in real time up to several days. Based on the extended time-course, the RTCA-SP could be also used to determine whether a smaller number of effector T-cells (as it probably occurs at the tumor site) completely lysed PDAC-cells or if due to an incomplete lysis tumor cells can regenerate. Similar killing patterns were observed with the γδ T-cell line of one representative healthy donor against Panc89 or Colo357 determined by either 51 Crrelease assay or RTCA-SP was used (Fig. 3) . Both PDAC-cell lines were weakly lysed by γδ T-cells without an additional stimulus. Over the extended time period of the RTCA-SP analysis, however, a more enhanced lysis of Panc89 cells than of Colo357 cells was evident compared to the 51 Cr-release assay (Fig. 3) . Moreover, the comparison of a 50:1 with a 5:1
Research. enhanced γδ T-cell-mediated lysis of PDAC-cells (Fig. 3) . Similar results were obtained with γδ T-cell lines from two additional donors in two independent experiments (data not shown).
A similarly designed control bsscFv resulted in a lysis comparable to that measured in the medium control (Fig. 3) . The addition of the bispecific antibody constructs to the tumor cells in the absence of γδ T-cells had no inhibitory/cytotoxic effect (data not shown).
Taken together, the [Her2xCD3] triggered the γδ T-cell lysis of largely resistant PDAC-cell lines, which was particularly evident at lower E/T ratio in the RTCA-SP assay. Her2) 2 xVγ9] were used instead of 1 μg/ml (Fig. 4G) . Additionally, the specificity of [(Her2) 2 xVγ9] and [Her2xCD3] was confirmed by the observation that these bispecific antibodies enhanced the γδ T-cell mediated lysis of Her2-positive PancTu-I cells, but not of Her2-negative cells (Fig. S5) .
Generation and effect of a selective γδ T-cell engager antibody construct

CD3-recruiting bsscFvs redirect all T-cells including immunosuppressive
To further substantiate these results, we analyzed the cytotoxic activity of additional γδ T-cell lines established from healthy donors and PDAC-patients against the three different PDAC- 
[(Her2) 2 xVγ9] enhances the release of cytolytic granules
The enhanced γδ T-cell cytotoxicity mediated by [(Her2) 2 xVγ9] prompted us to examine the mediators of this cytotoxic activity. The cytotoxic capacity of γδ T-cells can be mediated by CD95-CD178 interaction, but also through the release of cytolytic granules. As shown previously, PDAC-cells are almost resistant to CD95-induced cell death (15, 38) . Therefore, we examined the exocytosis with the CD107a-degranulation assay. Co-culturing of Colo357 cells with γδ T-cell lines of two healthy donors resulted in a weak cytotoxic activity of γδ Tcells as determined by RTCA-SP assay, which could be correlated with a weak induction of CD107a at the cell surface (Fig. 6A/B ). The addition of PAg enhanced γδ T-cell cytotoxicity and also the surface expression of CD107a, both of which could be further increased by adding [(Her2) 2 xVγ9] instead of PAg (Fig. 6A/B) . The release of granzyme B and perforin was measured in parallel by ELISA (Fig. 6C/D) . By using PancTu-I cells instead of Colo357 
Detection of tumor infiltrating γδ T-cells and effect of [(Her2) 2 xVγ9] on freshly isolated γδ T-cells in vitro and pre-activated γδ T cells in vivo
We asked whether [(Her2) 2 xVγ9] could also enhance the cytotoxicity of freshly isolated blood (Fig. 7B) . The γδ T-cell infiltration might be due to the high CXCL12 production of cancer-associated fibroblasts described elsewhere (39). Viey et al. reported about the CXCL12-mediated regulation of γδ T-cell migration to renal carcinoma (40) . We reported previously that the CXCL12-specific receptor CXCR4 is highly expressed on γδ T-cells (41) .
In contrast to the ductal epithelium, more CD3-positive γδ TCR-negative T-cells were localized in the stroma of the PDAC-patients (supplemental table 1 (Fig. S7D) did not influence tumor growth (Fig. 7D, S7B ). In 
reduction which was not significantly different from the control group, due to the heterogeneous outcome in this group (Fig. 7D, S7B ). Taken Treatment of PDAC-patients with gemcitabine, the standard therapy for PDAC, can inhibit MDSC, while enhancing cross-presentation of tumor-associated antigens by DC (45, 46 ). An exact mechanism of MDSC or gemcitabine on γδ T-cells has not been examined yet.
However, an increased γδ T-cell cytotoxicity after treatment with other chemotherapeutic 
agents in combination with n-BP has been described (47) . Moreover, gemcitabine resistance as well as a relapse based on residual population of cancer stem cells is frequently reported (48, 49) 
